Belite Bio (BLTE) director reports initial ADS and ordinary share stakes

Rhea-AI Filing Summary

Belite Bio director Chen Wan-Shan filed an initial ownership report showing direct holdings in the company. The filing lists 10,196 American depositary shares and 23,463 ordinary shares held directly. A footnote explains that each American depositary share represents one ordinary share of Belite Bio.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Chen Wan-Shan

(Last) (First) (Middle)

12750 HIGH BLUFF DRIVE SUITE 475

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
BELITE BIO, INC [ BLTE ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
American depositary share(1)	10,196	D
Ordinary Share	23,463	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Each American depositary share represents one ordinary share, par value US$0.0001 per share, of the Issuer.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Wan-Shan Chen	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Belite Bio (BLTE) director Chen Wan-Shan report owning in this Form 3?

Chen Wan-Shan reports direct ownership of 10,196 American depositary shares and 23,463 ordinary shares of Belite Bio. These figures represent current holdings, not a new purchase or sale, as part of an initial beneficial ownership statement.

Are the American depositary shares and ordinary shares of Belite Bio equivalent in this filing?

Yes. A footnote states that each American depositary share represents one ordinary share of Belite Bio, par value US$0.0001 per share. This means 10,196 American depositary shares correspond to 10,196 underlying ordinary shares on a one-for-one basis.

Does this Belite Bio (BLTE) Form 3 show any insider buying or selling activity?

No, the Form 3 reflects holdings only, with no reported insider purchases or sales. The transactions are classified as holdings with unknown transaction codes and a neutral net buy-sell direction in the transaction summary data.

Is Chen Wan-Shan’s ownership in Belite Bio classified as direct or indirect in this Form 3?

The ownership reported in this Form 3 is classified as direct. Both the American depositary shares and ordinary shares are marked with direct ownership codes, and no footnotes indicate that the shares are held through separate entities or indirect structures.

What role does Chen Wan-Shan hold at Belite Bio in this Form 3 disclosure?

Chen Wan-Shan is identified as a director of Belite Bio in this disclosure. The reporting person is not listed as an officer or ten-percent owner, and no additional roles beyond director are indicated in the filing metadata.